Article
The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors.
Cancer research - 15 Jul 2014
Izumchenko Evgeny, Chang Xiaofei, Michailidi Christina, Kagohara Luciane, Ravi Rajani, Paz Keren, Brait Mariana, Hoque Mohammad O, Ling Shizhang, Bedi Atul, Sidransky David
Abstract excerpt
Although specific mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) identify tumors that are responsive to EGFR tyrosine kinase inhibitors (TKI), these genetic alterations are present in only a minority of patients. Patients with tumors expressing wild-type EGFR lack reliable predictive markers of their clinical response to EGFR TKIs. Although epithelial-mesenchymal transition...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.